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GLOBAL EPIDEMIOLOGY
Kawasaki disease (KD) is a vasculitis of unknown etiology that predominantly affects infants and young children. The incidence of KD is increasing in many countries. Japan currently has an incidence of 234/100,000 children <5 years of age (corresponding to approximately 1 in 150 Japanese children having KD by age 10 years 1 ). The incidence is 134/100,000 in Korea and 69/100,000 in Taiwan. 2 The incidence in the Europe and Australia is approximately 6-9/100,000 and in the US 9-20/100,000. [2] [3] [4] [5] KD is increasingly reported from all regions of the world, particularly those undergoing rapid industrialization. There are few epidemiological data from resource-limited settings. Anecdotal evidence from India suggests that KD may overtake acute rheumatic fever as the commonest cause of pediatric acquired heart disease. 6 In Chandigarh, North India, the hospital-based incidence of KD is 4.5/100,000 children <15 years of age, 7 although this is probably an underestimate. It is important to recognize that KD is not limited to resource-rich countries; awareness of the features of KD and the possibility of the diagnosis in any young child with unexplained prolonged fever is relevant to all settings and populations. If KD is undiagnosed and untreated, the coronary artery complications, which may occur in up to 25%, are likely to contribute substantially to the increasing burden of cardiovascular disease in adults in the coming decades. Predictive models using US and Taiwanese epidemiologic data suggest that a large and growing patient population will require ongoing management of coronary artery disease following KD. 8 The rising number of KD patients with coronary aneurysms may also pose a significant burden on health resources in resource-limited settings.
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DIAGNOSING KD IN RESOURCE-LIMITED SETTINGS
Obstacles to the diagnosis and management of KD in resource-limited settings include lack of awareness, as well as financial and logistic constraints on access to appropriate investigations and evidence-based treatment. Familiarity with the epidemiology and with the diagnostic and associated clinical features, which are largely consistent in all ethnic groups, is therefore critical; these aspects have been reviewed in detail elsewhere. 2, 10, 11 The diagnosis of KD is made clinically and there is no diagnostic test. The cardinal diagnostic criteria, which individually lack specificity and sensitivity, can be particularly difficult in regions where tropical and other infections are common. Specialist referral (if available) may be financially challenging and is often delayed, such that diagnostic features, which appear sequentially or may be incomplete, may have resolved by the time of evaluation for KD.
Infections that may be particularly difficult to distinguish clinically from KD include measles and dengue. Measles is endemic in many regions and occurs sporadically worldwide. It shares many features with KD, including fever, rash, conjunctival injection and malaise. The conjunctival involvement in measles is often accompanied by discharge, whereas in KD the typical conjunctival injection has limbic sparing, but no discharge. Koplik's spots (a cluster of white lesions on the buccal mucosa opposite the lower molars) appear prior to the rash and are pathognomonic for measles. Respiratory symptoms are common in measles, but unusual in KD. The rash of measles, which typically appears after a few days of fever and when the respiratory symptoms are most severe, classically starts behind the ears and spreads caudally, becoming confluent before fading, which is also a feature that may help differentiate from the rash in KD. Desquamation may occur as the rash fades, but unlike KD, does not usually involve the palms and soles. Moreover, the rash in KD is less stereotypical, is usually most obvious on the trunk and may be transient or recurrent. These recurrences may differ from the original rash and can resemble psoriasis. Dengue can also be to distinguish from KD, as it may result in fever lasting up to 1 week and a rash that resembles that of measles. Thrombocytopenia is a feature of dengue and is only occasionally reported in KD, where thrombocytosis in the sub-acute phase is common.
A useful and probably unique sign in KD is inflammation/erythema at the site of Bacillus Calmette-Guérin vaccination, which may occur in up to 50% of patients 1-12 months after vaccination.
12
TREATMENT OF KD
The evidence-based treatment of KD is intravenous immunoglobulin (IVIg) as a single infusion of 2 g/kg, 11 usually given with aspirin (for which there is a limited evidence base for its use or dosing regimen). IVIg is an expensive human blood product and, in some settings, the costs of treatment for KD are prohibitive, especially if health insurance is not accessible for large sections of society. In India, as in many other resource-limited settings, the available preparations of IVIg are either manufactured by multinational companies (USD 330-415 per 5 g), or locally (USD 130-170 per 5 g). The latter preparations may be subject to less stringent quality and safety regulations, but may be the only affordable option.
At Chandigarh, North India, over 400 KD patients have been treated to date. Most families meet the costs of treatment themselves, but none has been denied treatment with IVIg because of financial hardship. When families have been unable to afford IVIg, philanthropic and non-governmental organizations have assisted. This may not be possible everywhere in India or in other resource-limited countries. Furthermore, IVIg itself may not be easily available in some countries, particularly in more remote areas, or may be priced so prohibitively that it is beyond the reach of many families.
The beneficial effects of IVIg are partly dose-dependent; doses less than 2 g/ kg may be associated with a higher incidence of coronary artery aneurysms. 13 Attempts have been made to stratify patients by risk of coronary artery damage and thereby reduce the IVIg dose in those considered at lower risk. A predictive score, based on standard laboratory parameters, has been developed to facilitate selective use of a reduced IVIg dose.
14 However, the sensitivity of the score is relatively poor (~60%), and it is unknown whether it is useful in non-Japanese populations; other KD predictive risk scores also have low sensitivity outside Japan. 15 
ADJUNCTIVE TREATMENT OPTIONS AND ALTERNATIVES TO IVIG
A more economical alternative for the treatment of KD in resource-limited countries is clearly needed. Corticosteroids, which are relatively cheap, have high oral bioavailability, and are available in most settings are a potential alternative. Indeed KD is unusual amongst the vasculitides in that corticosteroids are not recommended as primary treatment. Until a few years ago, it was thought that corticosteroids were potentially detrimental in KD, as early studies showed an association with worse outcome. 16 However, it is likely that this at least in part reflected inadvertent selection bias, as those with more severe KD received corticosteroids. Corticosteroids are recommended as "rescue" therapy if there is no response to initial infusion(s) of IVIg. 11 More recently the potential role of corticosteroids as adjunct primary therapy in addition to IVIg has been addressed in randomized trials, either in unselected patients, or in those considered at particularly high risk of coronary artery damage.
A multicenter, randomized, doubleblind trial from the US assessed primary treatment with IVIg (2 g/kg) and aspirin with or without a single dose methylprednisolone (30 mg/kg) in 199 unselected children. Addition of a single steroid dose to conventional therapy did not alter coronary artery outcomes. 17 A more recent prospective randomized, open-label trial in Japan enrolled only those assessed by a locally-derived risk score as being at particularly high risk of coronary damage. 18 Patients were randomized to a prolonged course of intravenous followed by oral prednisolone (or placebo), in addition to standard therapy with IVIg (2 g/kg) and aspirin. Coronary artery outcomes during the 4-week study period were significantly better in the corticosteroid group. However, the generalizability of these findings is uncertain; in particular, the scoring system on which selective recruitment was based does not perform well in non-Japanese patients. 19 As approximately 3 quarters of KD patients were excluded as they did not meet enrolment criteria (including those with coronary artery dilatation at presentation), it remains unclear whether this corticosteroid regimen would benefit KD patients more broadly. Moreover, the prolonged intravenous course of corticosteroids would itself incur significant additional costs. 19 Overall, these trial data are not directly applicable to resource-limited settings, as they assess corticosteroids in addition rather than as an alternative to IVIg. To date, there have been no published head-to-head comparisons of IVIg versus corticosteroids as primary treatment of KD. This partly reflects ethical issues that arise from withholding IVIg (an evidencebased treatment) in a trial setting where its use would otherwise be best practice. A more relevant comparison in resource-limited settings would be a trial of corticosteroids versus placebo in settings where IVIg is not available as part of clinical care. There are logistical difficulties in conducting such a trial, which would require sufficient infrastructure to diagnose KD with acceptable sensitivity and specificity, exclude other (usually infectious) differential diagnoses, and perform standardized echocardiographic assessment of coronary artery outcomes. There are also concerns regarding the use of corticosteroids in those who may have undiagnosed potentially life-threatening infections, particularly with Salmonella species, Mycobacterium tuberculosis and HIV. Diagnosis of these infections may be expensive and time-consuming. Optimal outcomes in KD treatment, at least with IVIg, are time-dependent; delaying treatment with IVIg beyond day 10 of KD is associated with poorer outcomes.
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Although there are no data on the optimal timing of corticosteroid therapy, the disease biology would suggest that delay of any effective treatment is likely to be detrimental. Therefore, a pragmatic approach may be careful observation and possibly appropriate empiric antibiotic treatment for commonly suspected pathogens during the initial steroid treatment, if diseases such as typhoid cannot be excluded. Other alternative treatment modalities (such as biologics) are currently less relevant in resourcelimited settings. To our knowledge, no studies have been reported on the use of agents such as infliximab for primary treatment of KD without concurrent IVIG. Anecdotally infliximab may offer potential cost benefits over IVIg in some settings.
RECOMMENDATIONS FOR THE TREATMENT OF KD IF IVIG IS UNAVAILABLE
The diagnosis and treatment of KD is often challenging, but may be more so in resource-limited settings where appropriate diagnostic facilities and IVIg are beyond the reach of many. International collaborative prospective trials of corticosteroids as primary treatment where IVIg either cannot be accessed or is unaffordable are warranted. Equipoise for such a trial exists because primary steroid administration in KD does not appear to be detrimental, and the benefits of steroid treatment without concomitant IVIg remain uncertain. Until trial data become available, it may be reasonable to consider primary treatment with steroids and possibly aspirin, if the diagnosis of KD is reasonably secure, serious infections have been excluded or empirically treated, and if IVIg is unavailable. The optimal steroid preparation, dose and © 2014 Lippincott Williams & Wilkins duration in these circumstances are unknown, but could be modeled after the RAISE trial regimen. 18 Hence, it may be reasonable to consider 2 mg/kg of oral prednisolone for 5-7 days, followed by a gradual tapering regimen. In children with severe KD, pulsed intravenous methylprednisolone (30 mg/kg/day for 3-5 days) followed by oral prednisolone for 2-3 weeks may be appropriate.
CONCLUSIONS
In resource-limited settings, KD represents an under-appreciated disease burden and the management is particularly difficult. If available, IVIg is the treatment of choice and should be given as soon as possible after diagnosis and ideally before day 10. If IVIg is unavailable, then steroids are a logical primary treatment, despite the lack of trial data and the limited published experience in this context. An evidence base for the appropriate use of widely available and affordable alternatives to IVIg is needed.
